内视镜逆行性胰造影市场 - 全球产业规模、份额、趋势、机会及预测（依产品、手术、最终用户、地区及竞争格局划分），2021-2031年

全球内视镜逆行性造影(ERCP) 市场预计将从 2025 年的 22.3 亿美元成长到 2031 年的 36.9 亿美元，复合年增长率为 8.76%。

内视镜逆行性造影）是一种特殊的医疗程序，它结合了上消化道内视镜检查和放射影像技术，用于诊断胰胆管病变。该市场的成长主要受全球人口老化和胆道疾病发病率上升的驱动。这些因素促使人们需要进行治疗干预，从而维持了对高效诊断和治疗方案的需求，进而推动了该行业的经济发展。

然而，该行业面临许多挑战，包括具备安全开展这项复杂手术所需专业知识的医生数量有限。熟练专业人员的短缺可能导致服务瓶颈，并限製手术量，尤其是在新兴市场。根据美国癌症协会的数据，预计到2025年，美国将新增约67,440例胰臟癌病例，这项数据凸显了此类治疗方法的迫切需求。因此，儘管医疗专业人员短缺，但持续的疾病负担仍然是推动内视镜治疗方案持续应用的关键因素。

市场驱动因素

随着医疗机构将感染预防和营运效率置于优先地位，并消除重复使用装置带来的交叉感染风险，一次性十二指肠镜的应用正在不断扩大。这项转变的驱动力来自监管指南以及省去复杂再处理流程带来的经济效益（降低医院的整体拥有成本）。根据Amb A/S公司于2025年11月发布的2024/25年度报告，该公司内视镜解决方案部门实现了15.4%的内部成长。这一数字表明，随着医疗机构更换老旧设备以提高病患安全，一次性技术的应用正在迅速普及。

此外，胆道和胰臟疾病发生率的上升是推动全球内视镜检查数量增加的主要临床因素。生活方式的改变和人口老化等因素导致恶性肿瘤和胆结石的发生率上升，因此需要精确的治疗和诊断干预。正如美国国立卫生研究院 (NIH) 于 2025 年 2 月发布的题为《全球胰腺癌发病率趋势》的论文中所述，预计 2022 年全球胰腺癌新发病例将达到约 510,922 例，并持续增长。为了应对这一流行病学趋势，製造商正在扩大产能。波士顿科学公司 (Boston Scientific) 的 2025 年报告预测，其 2024 年全年净销售额将达到 167.5 亿美元，比上年增长 17.6%。这一成长归功于产品系列的强劲表现。

市场挑战

全球内视镜逆行性造影（ERCP）市场面临的主要障碍之一是合格的ERCP操作人员短缺。由于该技术需要大量的专业培训和精湛的技术，因此合格的从业人员数量仍然有限。随着胰胆疾病发生率的上升，医疗基础设施无法相应扩大人力资源，造成了严重的瓶颈。这种短缺导致患者等待时间延长和手术量减少，这直接阻碍了市场的产生收入。

此外，ERCP（内视镜逆行性胰胆管摄影）学习曲线陡峭，令许多年轻医生望而却步，也给现有的医疗团队带来了额外的压力。医疗界的人口结构变化加剧了这种压力。根据美国医学院协会预测，到2036年，美国医疗系统将面临高达8.6万名医生的缺口，将严重影响胃肠病学等复杂专科的发展。治疗性介入需求与熟练内视镜医师供应之间的差距日益扩大，限制了市场成长，尤其是在教育基础设施本就薄弱的发展中地区和医疗资源匮乏地区。

市场趋势

人工智慧（AI）在影像分析领域的应用正成为内视镜逆行性胰胆管摄影术（ERCP）领域的一项变革性技术，显着提升了手术决策和诊断准确性。这些先进的演算法能够辅助内视镜医师即时鑑别不明原因的狭窄并检测胆道病变，从而最大限度地减少传统透视判读中固有的观察者间差异。除了诊断之外，这项技术还在不断发展，用于预测术后併发症，从而实现更个人化的患者照护。美国医学会在2025年1月发布的《数位健康趋势全国调查报告》中指出，到2024年，将有66%的医生采用人工智慧工具，比前一年增长78%，显示数据驱动型解决方案在胃肠病学领域正迅速普及。

同时，高清视觉化系统和数位胆道镜市场也取得了显着进展。这一趋势标誌着影像诊断方式正从间接放射成像转向直接成像，使临床医生能够在复杂碎石术和精准切片检查中直接、清晰地观察胰管和胆管。临床上对这些先进光学平台的需求日益增长，源于需要处理棘手的结石负荷，并在无需重复手术的情况下准确分期恶性肿瘤。Olympus Corporation在2024年11月发布的截至2024年9月的财年中期财务报告中指出，其内视镜解决方案业务的销售额增长了10.3%，这印证了上述需求。这一成长主要得益于欧洲和北美地区先进视觉化系统的强劲销售。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

5. 全球内视镜逆行性胰造影市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 依产品分类（内视镜、内视镜治疗设备、视觉化系统、能量设备、其他）
  • 依手术方式分类（胆道括约肌切开术、胆道支架置入术、胆道扩张术、胰管括约肌切开术、胰管支架置入术、胰管扩张术）
  • 依最终用户（医院、门诊机构）划分
  • 按地区
  • 按公司（2025 年）
• 市场地图

6. 北美内视镜逆行性胰造影市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

7. 欧洲内视镜逆行性胰造影市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

8. 亚太地区内视镜逆行性胰造影市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

9. 中东与非洲内视镜逆行性胰造影市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

10. 南美洲内视镜逆行性胰造影市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章 全球内视镜逆行性胰造影市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Olympus Corporation
• CONMED Corporation
• Boston Scientific Corporation
• Medtronic PLC
• TeleMed Systems, Inc.
• Ambu A/S
• FUJIFILM Holdings Corporation
• HOBBS MEDICAL INC
• Cook Group Incorporated
• HOYA Corporation

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Endoscopic Retrograde Cholangiopancreatography Market is projected to expand from a valuation of USD 2.23 Billion in 2025 to USD 3.69 Billion by 2031, reflecting a compound annual growth rate of 8.76%. As a specialized medical intervention, Endoscopic Retrograde Cholangiopancreatography integrates upper gastrointestinal endoscopy with radiographic imaging to address pathologies within the pancreatic and bile ducts. This market trajectory is primarily propelled by an aging global demographic and an increasing incidence of biliary disorders, factors that necessitate therapeutic measures and sustain the demand for efficient diagnostic and treatment solutions, thereby underpinning the sector's financial progress.

Conversely, the industry confronts a significant obstacle regarding the limited availability of physicians possessing the expertise to safely execute this intricate procedure. This shortage of skilled professionals threatens to create service bottlenecks and restrict the volume of procedures, particularly within emerging markets. Data from the American Cancer Society indicates that approximately 67,440 individuals in the United States will receive a pancreatic cancer diagnosis in 2025, a statistic that underscores the urgent need for these interventions. Consequently, the persistent burden of disease remains a critical factor fueling the continued utilization of endoscopic solutions despite workforce constraints.

Market Driver

The increasing implementation of single-use duodenoscopes is significantly reshaping the market as healthcare facilities emphasize infection prevention and operational efficiency to eliminate cross-contamination risks linked to reusable instruments. This shift is accelerated by regulatory guidance and the economic advantages of discarding complex reprocessing procedures, which lowers the overall cost of ownership for hospitals. According to the 'Annual Report 2024/25' published by Ambu A/S in November 2025, the company achieved an organic growth rate of 15.4 percent within its Endoscopy Solutions division, a figure that highlights the rapid transition toward disposable technologies as institutions upgrade legacy equipment to improve patient safety.

Additionally, the rising incidence of biliary and pancreatic conditions acts as the central clinical force increasing the global volume of endoscopic procedures. Factors such as lifestyle shifts and an aging population are leading to higher rates of malignancies and gallstones, requiring accurate therapeutic and diagnostic interventions. As noted by the National Institutes of Health in the February 2025 article 'Trends in the Global Incidence of Pancreatic Cancer', the global disease burden involved an estimated 510,922 new cases in the 2022 reference year, with forecasts suggesting a continuing rise. This epidemiological trend drives manufacturers to expand capabilities, reflected in Boston Scientific's 2025 report of 16.75 billion dollars in full-year 2024 net sales, a 17.6 percent increase attributed to strong medical and surgical portfolio performance.

Market Challenge

A primary hurdle facing the Global Endoscopic Retrograde Cholangiopancreatography Market is the shortage of medical professionals qualified to perform ERCP procedures. Because this technique demands extensive specialized training and a high degree of technical skill, the number of capable practitioners remains limited. As the incidence of pancreatic and biliary disorders grows, the inability of healthcare infrastructures to expand their workforce proportionally creates severe bottlenecks. These deficiencies result in extended patient wait times and diminished procedure volumes, factors that directly impede the market's revenue generation capabilities.

Moreover, the steep learning curve required for ERCP dissuades many emerging physicians from pursuing this specialty, placing further strain on the current workforce. This pressure is compounded by demographic changes within the medical community itself. According to the Association of American Medical Colleges, the United States healthcare system was projected in 2024 to encounter a physician shortage of up to 86,000 by 2036, a deficit that critically affects complex fields such as gastroenterology. This growing disparity between the demand for therapeutic interventions and the supply of skilled endoscopists limits market growth, particularly in developing and underserved areas where educational infrastructure is already sparse.

Market Trends

The incorporation of artificial intelligence into image analysis is emerging as a transformative element in the ERCP sector, significantly improving procedural decision-making and diagnostic accuracy. These sophisticated algorithms assist endoscopists in differentiating indeterminate strictures and detecting biliary lesions in real-time, thereby minimizing the inter-observer variability inherent in conventional fluoroscopic interpretation. Beyond diagnostics, this technology is evolving to forecast post-procedure complications, facilitating more tailored patient care. In a January 2025 national survey report on digital health trends, the American Medical Association noted that 66 percent of physicians employed artificial intelligence tools in 2024, a 78 percent increase from the prior year that illustrates the rapid adoption of data-driven solutions in gastroenterology.

Concurrently, the market is experiencing significant progress in high-definition visualization systems and digital cholangioscopy. This trend represents a major shift away from indirect radiographic imaging, enabling clinicians to obtain clear, direct views of the pancreatic and bile ducts for complex lithotripsy and precise biopsies. The escalating clinical demand for these advanced optical platforms stems from the need to manage difficult stone burdens and accurately stage malignancies without resorting to repeated procedures. Evidence of this demand is found in Olympus Corporation's 'Consolidated Financial Results for the Six Months Ended September 30, 2024', released in November 2024, which reported a 10.3 percent revenue increase in its Endoscopic Solutions Business, driven largely by strong sales of advanced visualization systems in Europe and North America.

Key Market Players

• Olympus Corporation
• CONMED Corporation
• Boston Scientific Corporation
• Medtronic PLC
• TeleMed Systems, Inc.
• Ambu A/S
• FUJIFILM Holdings Corporation
• HOBBS MEDICAL INC
• Cook Group Incorporated
• HOYA Corporation

Report Scope

In this report, the Global Endoscopic Retrograde Cholangiopancreatography Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Endoscopic Retrograde Cholangiopancreatography Market, By Product

• Endoscopes
• Endotherapy Devices
• Visualization Systems
• Energy Devices
• Others

Endoscopic Retrograde Cholangiopancreatography Market, By Procedure

• Biliary Sphincterotomy
• Biliary Stenting
• Biliary Dilatation
• Pancreatic Sphincterotomy
• Pancreatic Duct Stenting
• Pancreatic Duct Dilation

Endoscopic Retrograde Cholangiopancreatography Market, By End User

• Hospitals
• Outpatient Facilities

Endoscopic Retrograde Cholangiopancreatography Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Endoscopic Retrograde Cholangiopancreatography Market.

Available Customizations:

Global Endoscopic Retrograde Cholangiopancreatography Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Endoscopic Retrograde Cholangiopancreatography Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Endoscopes, Endotherapy Devices, Visualization Systems, Energy Devices, Others)
  • 5.2.2. By Procedure (Biliary Sphincterotomy, Biliary Stenting, Biliary Dilatation, Pancreatic Sphincterotomy, Pancreatic Duct Stenting, Pancreatic Duct Dilation)
  • 5.2.3. By End User (Hospitals, Outpatient Facilities)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Endoscopic Retrograde Cholangiopancreatography Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Procedure
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Procedure
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Procedure
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Procedure
      • 6.3.3.2.3. By End User

7. Europe Endoscopic Retrograde Cholangiopancreatography Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Procedure
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Procedure
      • 7.3.1.2.3. By End User
  • 7.3.2. France Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Procedure
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Procedure
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Procedure
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Procedure
      • 7.3.5.2.3. By End User

8. Asia Pacific Endoscopic Retrograde Cholangiopancreatography Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Procedure
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Procedure
      • 8.3.1.2.3. By End User
  • 8.3.2. India Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Procedure
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Procedure
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Procedure
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Procedure
      • 8.3.5.2.3. By End User

9. Middle East & Africa Endoscopic Retrograde Cholangiopancreatography Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Procedure
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Procedure
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Procedure
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Procedure
      • 9.3.3.2.3. By End User

10. South America Endoscopic Retrograde Cholangiopancreatography Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Procedure
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Procedure
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Procedure
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Endoscopic Retrograde Cholangiopancreatography Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Procedure
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Endoscopic Retrograde Cholangiopancreatography Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Olympus Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. CONMED Corporation
• 15.3. Boston Scientific Corporation
• 15.4. Medtronic PLC
• 15.5. TeleMed Systems, Inc.
• 15.6. Ambu A/S
• 15.7. FUJIFILM Holdings Corporation
• 15.8. HOBBS MEDICAL INC
• 15.9. Cook Group Incorporated
• 15.10. HOYA Corporation

16. Strategic Recommendations

17. About Us & Disclaimer